[go: up one dir, main page]

MX2016013735A - Cristales novedosos de compuesto tetraciclico. - Google Patents

Cristales novedosos de compuesto tetraciclico.

Info

Publication number
MX2016013735A
MX2016013735A MX2016013735A MX2016013735A MX2016013735A MX 2016013735 A MX2016013735 A MX 2016013735A MX 2016013735 A MX2016013735 A MX 2016013735A MX 2016013735 A MX2016013735 A MX 2016013735A MX 2016013735 A MX2016013735 A MX 2016013735A
Authority
MX
Mexico
Prior art keywords
tetraciclic
compound
new glasses
glasses
type
Prior art date
Application number
MX2016013735A
Other languages
English (en)
Other versions
MX378186B (es
Inventor
Tanaka Kota
Ueto Takamitsu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54332607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013735(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2016013735A publication Critical patent/MX2016013735A/es
Publication of MX378186B publication Critical patent/MX378186B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a cristales de tipo II y tipo III de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-ox o-6,11-dihidro-5H-benzo[b]carbazol-3-carbonitrilo que es un cristal novedoso farmacéuticamente útil.
MX2016013735A 2014-04-25 2015-04-24 Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo. MX378186B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014092102 2014-04-25
PCT/JP2015/062516 WO2015163447A1 (ja) 2014-04-25 2015-04-24 ４環性化合物の新規結晶

Publications (2)

Publication Number Publication Date
MX2016013735A true MX2016013735A (es) 2017-03-09
MX378186B MX378186B (es) 2025-03-10

Family

ID=54332607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013735A MX378186B (es) 2014-04-25 2015-04-24 Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo.

Country Status (9)

Country Link
US (1) US9714229B2 (es)
EP (1) EP3135671B1 (es)
JP (1) JP6873698B2 (es)
KR (2) KR20220042486A (es)
CN (2) CN113416179A (es)
CA (1) CA2946268A1 (es)
MX (1) MX378186B (es)
RU (1) RU2016146119A (es)
WO (1) WO2015163447A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58855B1 (sr) * 2009-06-10 2019-07-31 Chugai Pharmaceutical Co Ltd Tetraciklična jedinjenja
JP4918630B1 (ja) 2010-08-20 2012-04-18 中外製薬株式会社 ４環性化合物を含む組成物
MX389105B (es) 2012-09-25 2025-03-20 Chugai Pharmaceutical Co Ltd Inhibidor de quinasas reordenadas durante la transfeccion (ret).
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
CN106456556A (zh) 2014-06-18 2017-02-22 豪夫迈·罗氏有限公司 包含非离子性表面活性剂的新型药物组合物
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CA2973857C (en) 2015-01-16 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Combination drug
WO2019008520A1 (en) 2017-07-05 2019-01-10 Fresenius Kabi Oncology Limited PROCESS FOR THE PREPARATION OF ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
AU2019293777A1 (en) 2018-06-29 2021-02-18 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing poorly-soluble basic medicine
IL281079B2 (en) 2018-09-04 2024-12-01 Chugai Pharmaceutical Co Ltd Method of producing a tetracyclic compound
EP3556754A1 (en) 2018-12-07 2019-10-23 Fresenius Kabi iPSUM S.r.l. Process for the preparation of alectinib
AR121187A1 (es) 2019-12-27 2022-04-27 Chugai Pharmaceutical Co Ltd Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene
MX2023008735A (es) 2021-01-29 2023-08-01 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para el tratamiento de cancer pediatrico.
WO2023074785A1 (ja) 2021-10-28 2023-05-04 中外製薬株式会社 シロップ剤
EP4482830A1 (en) 2022-02-22 2025-01-01 Synthon B.V. Solid forms of alectinib and alectinib salts
WO2025045901A1 (en) 2023-08-31 2025-03-06 F. Hoffmann-La Roche Ag Treatment of non small cell lung cancer with alectinib
WO2025104045A1 (en) 2023-11-15 2025-05-22 F. Hoffmann-La Roche Ag Alectinib for the treatment of alk fusion-positive solid or cns tumours

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
DE69505470T2 (de) 1994-08-04 1999-05-12 F. Hoffmann-La Roche Ag, Basel Pyrrolocarbazol
JP3235840B2 (ja) 1996-05-01 2001-12-04 イーライ・リリー・アンド・カンパニー プロテインキナーゼｃのハロ置換阻害剤
CA2372032A1 (en) 1999-05-14 2000-11-23 Rodney W. Rickards Compounds and therapeutic methods
EP1364643A4 (en) 2000-12-01 2009-07-15 Kyowa Hakko Kogyo Kk COMPOSITION WITH IMPROVED SOLUBILITY OR ORAL ABSORBIBILITY
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
ES2263862T3 (es) 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
US7687524B2 (en) 2003-12-12 2010-03-30 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
EP1725530A1 (en) 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CA2578066C (en) 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
KR20080056288A (ko) 2005-11-07 2008-06-20 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
CA2693901C (en) 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
KR20120034639A (ko) 2009-05-07 2012-04-12 아스트라제네카 아베 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
RS58855B1 (sr) * 2009-06-10 2019-07-31 Chugai Pharmaceutical Co Ltd Tetraciklična jedinjenja
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP4918630B1 (ja) 2010-08-20 2012-04-18 中外製薬株式会社 ４環性化合物を含む組成物
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
MX389105B (es) * 2012-09-25 2025-03-20 Chugai Pharmaceutical Co Ltd Inhibidor de quinasas reordenadas durante la transfeccion (ret).
JP2015185406A (ja) 2014-03-25 2015-10-22 トヨタ自動車株式会社 燃料電池システム及び燃料電池の水分量制御方法

Also Published As

Publication number Publication date
RU2016146119A3 (es) 2018-07-04
KR20220042486A (ko) 2022-04-05
JPWO2015163447A1 (ja) 2017-04-20
WO2015163447A1 (ja) 2015-10-29
US20170081306A1 (en) 2017-03-23
EP3135671A1 (en) 2017-03-01
KR20160142383A (ko) 2016-12-12
MX378186B (es) 2025-03-10
CN106458967A (zh) 2017-02-22
CN113416179A (zh) 2021-09-21
RU2016146119A (ru) 2018-05-29
CA2946268A1 (en) 2015-10-29
EP3135671B1 (en) 2019-09-18
JP6873698B2 (ja) 2021-05-19
US9714229B2 (en) 2017-07-25
EP3135671A4 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
MX2016013735A (es) Cristales novedosos de compuesto tetraciclico.
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
EA201790570A1 (ru) Модуляторы р2х7
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
DOP2016000211A (es) Pirazinas moduladoras de gpr6
UY34504A (es) Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
IN2013CH04906A (es)
IN2013MU01113A (es)
IN2014DN09451A (es)
MX382659B (es) Proceso para la preparación de derivados de tiazol.
EA201691362A1 (ru) Способы получения конденсированных гетероциклических модуляторов ионных каналов
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
DOP2017000070A (es) Inhibidores cristalinos de bace
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
IN2015CH02092A (es)
IN2014CH00444A (es)
WO2014170909A3 (en) Process for pomalidomide